Savara (NASDAQ:SVRA) Price Target Lowered to $6.00 at HC Wainwright

Savara (NASDAQ:SVRA) had its price objective reduced by equities research analysts at HC Wainwright from $10.00 to $6.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 88.09% from the stock’s current price. HC Wainwright also issued estimates for Savara’s Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.46) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at $0.00 EPS.

A number of other brokerages have also recently issued reports on SVRA. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and issued a $5.00 target price (down from $7.00) on shares of Savara in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Savara currently has an average rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Trading Down 1.8 %

NASDAQ:SVRA opened at $3.19 on Wednesday. The stock has a 50-day simple moving average of $3.93 and a 200-day simple moving average of $4.21. The stock has a market cap of $525.08 million, a P/E ratio of -7.42 and a beta of 1.02. Savara has a 1 year low of $3.09 and a 1 year high of $5.70. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). As a group, analysts anticipate that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in shares of Savara by 92.3% during the 1st quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock worth $366,000 after buying an additional 35,269 shares in the last quarter. Swiss National Bank purchased a new position in shares of Savara during the 1st quarter worth approximately $732,000. ProShare Advisors LLC raised its stake in shares of Savara by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after buying an additional 2,114 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after buying an additional 148,673 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co purchased a new position in shares of Savara during the 1st quarter worth approximately $35,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.